• Nawal Helmi, Hani Choudhry, M Qari, Taha A Kumosani, Abdulrahman L Al-Malki, Said Salama Moselhy, and Afnan T Kumosani.
• Biochemistry Department, Faculty of science, King Abdulaziz University (KAU), Jeddah, Kingdom of Saudi Arabia.
• Afr Health Sci. 2018 Sep 1; 18 (3): 720726720-726.

BackgroundThe current study evaluated level of serum asymmetric dimethylarginine (ADMA) and its association to cardiac biomarkers in thalassemia patients for early diagnosis of abnormality in myocardial infarction.Subjects And MethodsThis study was conducted on 80 subjects divided into four groups each with 20 subjects. Group I: Control: healthy subjects. Group II: Myocardial infarction: Patients with elevated serum troponin T. Group III: thalassemia patients. Group IV: thalassemia with myocardial infarction patients: Included 20 thalassemia patients with Myocardial infarction. Serum samples were subjected for assay of creatine kinase (CK:MB), Lactate dehydrogenase, troponin I, ADMA, Serum MDA level was determined.ResultsData obtained showed that serum CKMB, LDH1, AST, Troponin T and ADMA levels were significant elevated in MI with or without Thalassemia compared with control groups. Serum MDA was statistically significantly elevated in MI with or without Thalassemia compared with control groups. The serum level of troponin T showed an area under curve (AUC) of 0.92, (sensitivity 91.0 % and specificity, 88%). Also, the ADMA supported the diagnostic profile, showing an AUC of 0.85 with (sensitivity, 92.0%; specificity, 91,9%).ConclusionSerum ADMA is sensitive marker for incidence of MI in thalassemia patients.

26 keywords...

hide…